Office of Innovation and Industry Alliances
Office of Innovation and Industry Alliances
To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| Protein Diagnostic: Characterization of Quantum Dots for Ovarian Cancer Detection | 04A064 |
| Protein Signature: Discriminating Common Adenocarcinomas | 05A014 |
| Genetic Signature: Metastatic Melanoma Stage Identification | 06B073 |
| Plasma Protein Biomarker: Diagnosis of Ovarian Cancer | 06B098 |
| Protein Biomarker: Predicting Response to Immunosuppression in MDS | 07A056 |
| Genetic Signature: Predicting Tumor Aggressiveness | 07B108 |
| Protein Biomarker: Diagnostic Marker for AML and MPD | 07B113 |
| Genetic Signature: Malignancy Risk Signature to Predict High-Risk Normal Breast Tissues | 08A016 |
| Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence | 08MA005 |
| Genetic Signature: Lymph Node Formation for Prognosis of Colorectal Cancer | 09MA014 |
| Protein Biomarker/Genetic Signature: Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP) | 10MA009 |
| Genetic Signature: Predicting High Grade Glioma Outcomes Using Senescence Associated Genes | 10MA013 |
| Molecular Imaging Probe: Non-invasive Detection of Breast Cancer in Lymph Nodes | 10MA024 |
| Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery | 10MB069N |
| Genetic Signature: CREB Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking | 11MA006 |
| Protein Diagnostic: Protein-Protein Interaction (PPI) Biomarkers | 11MA014 |
| Imaging: Digital Pathology Tool to Grade Breast Cancer Histological Images | 11MA022 |
| Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma | 11MA026N |
| Genetic Signature: Method of Detecting MDS Using hTERT Activity | 11MB061N |
| Molecular Imaging Probe: Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes | 11MB064 |
| Genetic Signature: Predicting Response to Cancer Immunotherapy | 11MB069 |
| Protein Signature: Method of Diagnosing Chronic Lymphocytic Leukemia | 11MB072N |
| Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins | 11MB087N |
| Genetic Signature: Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC | 12MA023N |
| Genetic Signature: O-glycan Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking | 12MA034 |
| Genetic Signature: Determining Prostate Cancer Recurrence Using Polymorphisms in Angiogenesis Genes | 12MA045 |
| Molecular Imaging Probe: Probes for Lung Cancer Intraoperative Guidance | 12MA050N |
| Genetic Signature: E2F/Rb Pathway Signature to Predict Benefit from Adjuvant Chemo in NSCLC | 12MA069 |
| Molecular Imaging Probe: A Novel 18F Scaffold for Preparing Targeted PET Imaging Probes | 12MB104 |
| Protein Diagnostic: Phosphorylated STAT3 Protein as a Biomarker of Graft Versus Host Disease | 13MA002 |
| Multiplex Diagnostic: RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma | 13MA009 |
| Genetic Signature: Predicting Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer | 13MA036 |
| Imaging: Decision Support Tool for Oncology Treatment that Analyzes Radiological Images | 13MB047 |
| Cell Imaging: Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma | 13MB048N |
| Molecular Imaging: Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule Diagnosis | 13MB054 |
| Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma | 13MB055 |
| Molecular Imaging: PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging | 13MB056N |
| miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs) | 13MB078 |
| miRNA Diagnostic: Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma | 13MB080 |
| Protein Biomarker: Expression of WEE1 and PAXIP1 to Predict Respond to WEE1 Inhibitors | 14MA001 |
| Genetic Signature: Predicting Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery | 14MA008 |
| Genetic Signature: Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy | 14MA052N |
| WEE1: Small Molecule WEE1 Inhibitor to Treat Cancer that Inhibits WEE1 Phosphorylation of H2B but not Cdc2 | 14MB092 |
| Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients | 15MA015 |
| Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation May Be Specific Biomarkers for MDS | 15MA021N |
| Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration | 15MA031N |
| Molecular Imaging Probe: In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes | 15MB042N |
| Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression | 15MB065 |
| Genetic Signature: Distinguishing Lung Carcinoma from Metastatic Head & Neck Carcinoma | 16MB040 |
| Protein Biomarker: Measuring MRE11 in Muscle-Invasive Bladder Cancer to Predict whether Cystectomy (bladder removal) would have a Better Outcome than Bladder-sparing Therapy with Chemoradiation | 16MB041 |
| Protein Biomarker: Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients treated with Lenalidomide | 16MB042 |
| Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent | 16MB044 |
| miRNA Diagnostic: Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma | 16MB066 |
| miRNA Diagnostic: miRNA Signature combined with Radiological Features for Non-invasive Early Detection of Malignancy in IPMN | 17MA001 |
| Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment | 17MA025 |
| Genetic Signature: Distinguishing Urothelial Carcinoma from Squamous Cell Carcinoma (Primary Lung Carcinoma and Metastatic Head & Neck Carcinoma) | 17MB044 |